Detection of hepcidin biomarker in plasma of patients with stomach tumor before and after treatment

Naimeh Ashna moghadam,1,* Bahman bashardoust,2 Mohammad zaeifizadeh,3

1. Department of Biology,Islamic Azad University of Ardabil Branch
2. Ardabil medical university
3. Department of Biology,Islamic Azad University of Ardabil Branch



: cancer is a very important public health problem, which is the main cause of death inindustrialized countries and increases based on global statics. to reduce its mortality and to detect it asearly as possible, new markers should be identified. hepcidin is a small peptide produced in liver inresponse to anemia or inflammation, with antimicrobial effect, which is iron intake regulator. it hasbeen shown that this hormone increases in cancer cells. therefore the same, it can be used as a tumor marker to detect cancer.


In this study, 29 patients with gastric cancer diagnosed and received chemotherapy between february and august 2017 and 15 healthy subjects were enrolled. hepcidin levels were measured by elisa method(s) using specified kit(s) procured commercially and finally evaluated with spss software. in 14 patients, hepcidin levels before and after chemotherapy were also measured.


Two groups were comparable regarding age and gender. cancer patients had significantly higher hepcidine levels compared to healthy subjects (29.46+-5.66 vs. 17.46+_2.01, p=0.01). the reduction in serum hepcidin levels after treatment was not significant (37.59+_34.18 befor vs. 13.72+_7.82 after, p=0.06).


our results showed higher levels of serum hepcidin in gastric cancer patients, with no significant difference before and after chemotherapy. it is possible that this marker have a role in the early diagnosis of gastric cancer, but further studies are recommended.


stomach cancer, biomarker, hepcidin